CTLA4 and neoplasm: The most studied checkpoint receptors in tumor immunotherapy targets are cytotoxic T lymphocyte antigen-4 (CTLA-4) and the programmed death-1 (PD-1) receptor, which downregulates the activation, proliferation, and function of T cells through different mechanisms [28, 29].